The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications

Parth K. Modi, Ye Wang, Peter S. Kirk, James M. Dupree, Eric Singer, Steven L. Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To determine the impact of physicians’ financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. Materials and Methods: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs. Results: The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect. Conclusion: There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalUrology
Volume117
DOIs
StatePublished - Jul 1 2018

Fingerprint

Overactive Urinary Bladder
Industry
Odds Ratio
Drug Prescriptions
Medicare Part D
Drug Industry
Prescriptions
Logistic Models
Databases
Physicians
Pharmaceutical Preparations
mirabegron
Solifenacin Succinate
fesoterodine
silodosin

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Modi, Parth K. ; Wang, Ye ; Kirk, Peter S. ; Dupree, James M. ; Singer, Eric ; Chang, Steven L. / The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. In: Urology. 2018 ; Vol. 117. pp. 50-56.
@article{d32449607dc4461a86f125fa42c3bca1,
title = "The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications",
abstract = "Objective: To determine the impact of physicians’ financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. Materials and Methods: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs. Results: The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect. Conclusion: There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.",
author = "Modi, {Parth K.} and Ye Wang and Kirk, {Peter S.} and Dupree, {James M.} and Eric Singer and Chang, {Steven L.}",
year = "2018",
month = "7",
day = "1",
doi = "https://doi.org/10.1016/j.urology.2018.04.008",
language = "English (US)",
volume = "117",
pages = "50--56",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. / Modi, Parth K.; Wang, Ye; Kirk, Peter S.; Dupree, James M.; Singer, Eric; Chang, Steven L.

In: Urology, Vol. 117, 01.07.2018, p. 50-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications

AU - Modi, Parth K.

AU - Wang, Ye

AU - Kirk, Peter S.

AU - Dupree, James M.

AU - Singer, Eric

AU - Chang, Steven L.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: To determine the impact of physicians’ financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. Materials and Methods: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs. Results: The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect. Conclusion: There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.

AB - Objective: To determine the impact of physicians’ financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. Materials and Methods: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs. Results: The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect. Conclusion: There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.

UR - http://www.scopus.com/inward/record.url?scp=85047324224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047324224&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.urology.2018.04.008

DO - https://doi.org/10.1016/j.urology.2018.04.008

M3 - Article

C2 - 29680480

VL - 117

SP - 50

EP - 56

JO - Urology

JF - Urology

SN - 0090-4295

ER -